Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNB 011

Next Previous
Drug Profile

SNB 011

Alternative Names: Airnecflu®; Pentarlandir™; Pentarlandir™ Ultrapure and Potent Tannic Acid; Pentarlandir™ UPPTA; SNB-01; SNB-011

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SyneuRx International (Taiwan) corp
  • Class Anti-inflammatories; Antivirals; Biopolymers; Small molecules
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors; Cytokine inhibitors; D amino acid oxidase inhibitors; Serine protease inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Anxiety disorders; Depressive disorders; Influenza virus infections; Memory disorders

Most Recent Events

  • 18 Sep 2024 Preclinical trials in Influenza virus infections in Taiwan (PO)
  • 02 Aug 2022 Preclinical trials in COVID-2019 infections in Taiwan (Inhalation) (SyneuRx pipeline, August 2022)
  • 02 Aug 2022 SyneuRx plans a first-in-human trial for COVID-2019 infections in the second half of 2022 (SyneuRx pipeline, August 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top